Table 1. Participants’ characteristics across groups, as tested with linear regression (the t and p value refer to the main effect of Group).
BMI = Body Mass Index; MVC = Maximum Voluntary Contraction; PANAS = Positive and Negative Affective Schedule; M = Mean; SD = Standard deviation.
| Amisulpride | Naltrexone | Placebo | Group differences | |
|---|---|---|---|---|
| N (male, female) | 42 (14, 28) | 44 (14, 30) | 45 (15, 30) | |
| Age M (SD) | 23.7 (4.1) | 22.9 (2.8) | 23.1 (3.7) | t = −0.73, p=0.46 |
| BMI M (SD) | 22.7 (2.5) | 23.0 (2.3) | 22.2 (2.5) | t = −0.99, p=0.32 |
| MVC M (SD) | 211.9 (86.3) | 208.7 (81.8) | 215.3 (73.1) | t = 0.19, p=0.85 |
| PANAS pos T1 M (SD) | 30.5 (5.4) | 29.7 (7.3) | 29.4 (6.7) | t = −0.8, p=0.42 |
| PANAS neg T1 M (SD) | 12.1 (3.2) | 14.3 (7.5) | 11.5 (2.1) | t = −0.7, p=0.52 |
| PANAS pos T2 M (SD) | 27.1 (6.3) | 24.7 (8.0) | 26.7 (7.4) | t = −0.3, p=0.80 |
| PANAS neg T2 M (SD) | 10.1 (2.8) | 12.1 (5.5) | 10.5 (0.9) | t = −0.5, p=0.58 |
| Nausea T1 M (SD) | 1.05 (0.2) | 1.02 (0.1) | 1.00 (0.0) | t = −1.5, p=0.14 |
| Nausea T2 M (SD) | 1.00 (0.0) | 1.20 (0.6) | 1.00 (0.0) | t = −0.1, p=0.93 |